AQA-0622 is under clinical development by Aquavit Pharmaceuticals and currently in Phase I for Macular Degeneration. According to GlobalData, Phase I drugs for Macular Degeneration have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AQA-0622’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AQA-0622 overview

AQA-0622 is under development for the treatment of macular degeneration.

Aquavit Pharmaceuticals overview

Aquavit Pharmaceuticals is an healthcare company which focuses on discovering, developing and commercializing innovative pharmaceuticals, medical devices and health technologies. Aquavit Pharmaceuticals is headquartered in New York, New York, the US.

For a complete picture of AQA-0622’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.